ResMed’s Digital Dominance: A 10% Upside Opportunity for Long-Term Investors
By stockpickr AI | March 9, 2026 | 10 min read
Investment Summary
ResMed is a dominant player in the respiratory medical device sector and is currently fairly valued to slightly undervalued based on long-term DCF projections amid strong demand for its digital health ecosystem.
Investment Recommendation
Buy
Fair Value: $275.40
Current Price: $249.50
Upside/Downside: +10.3%
The DCF analysis indicates an intrinsic value near $275 per share, suggesting a moderate upside from current levels. The primary valuation driver is the expected sustained growth in cloud-based software revenue and international expansion.
Key Metrics
- Market Cap: $36.6B
- P/E Ratio: 33.2x
- Forward P/E: 26.8x
- Revenue Growth (YoY): 12%
- Net Margin: 24.5%
- ROE: 28.4%
- Debt/Equity: 0.28
- Dividend Yield: 0.82%
Strengths
- Recurring revenue base with over 24 million cloud-connectable medical devices currently in the field globally.
- Strong operating leverage, maintaining net margins consistently above 20% due to high-margin digital health ecosystem.
- Market leadership in the sleep and respiratory care market with significant barriers to entry.
- Solid balance sheet with a low debt-to-equity ratio of 0.28, providing flexibility for strategic R&D and M&A.
Risk Factors
- Potential long-term market disruption caused by the rapid adoption of GLP-1 weight-loss medications.
- Supply chain dependency on semiconductor chips and specialized electronic components.
- Heightened regulatory scrutiny in international healthcare markets impacting pricing power.